公开(公告)号：US6127136A

公开(公告)日：2000-10-03

申请号：US601645

申请日：1996-02-14

申请人： Geoffrey D. Wheelock

发明人： Geoffrey D. Wheelock

IPC分类号： G01N33/00 ,  G01N33/53 ,  G01N33/567 ,  G01N33/548

CPC分类号： G01N33/567 ,  G01N33/5308 ,  G01N2333/705 ,  G01N2430/40 ,  Y10S436/815

摘要： A method of detecting dioxin-like compounds consisting essentially of the group of compounds: polychlorinated dibenzodioxins, polychlorinated dibenzofurans, polychlorinated biphenyls, and structural analogues thereof which exhibit biological activity characteristic of polychlorinated dibenzodioxins, polychlorinated dibenzofurans, polychlorinated biphenyls. The assay includes: 1) an inactive Ah receptor in a form capable of binding to the dioxin-like compounds and being transformed to an active form that forms a complex with ARNT and binds a dioxin responsive element, and 2) a quantity of ARNT sufficient to optimize Ah receptor transformation. A test sample is contacted with the assay under conditions effective to bind the dioxin-like compounds to the Ah receptor and allow transformation of the Ah receptor to an active form that forms a complex with ARNT. The presence of the complex containing the transformed Ah receptor and the ARNT is detected. The presence of the complex containing the transformed Ah receptor and the ARNT is detected with an antibody with a region capable of binding to the ARNT when associated with the complex.

摘要翻译： 检测二恶英类化合物的方法，其基本上由化合物组合：多氯二苯并二恶英，多氯二苯并呋喃，多氯联苯及其结构类似物，其表现出多氯二苯并二恶英，多氯二苯并呋喃，多氯联苯的生物活性。 该测定包括：1）能够结合二恶英类化合物并转化成与ARNT形成复合物并结合二恶英应答元件的活性形式的无活性Ah受体，以及2）足量的ARNT量 以优化Ah受体转化。 在有效将二恶英类化合物与Ah受体结合的条件下，将测试样品与测定接触，并允许将Ah受体转化成与ARNT形成复合物的活性形式。 检测到含有转化的Ah受体和ARNT的复合物的存在。 含有转化的Ah受体和ARNT的复合物的存在用具有能够与复合物结合的ARNT的区域的抗体检测。

公开(公告)号：US6140063A

公开(公告)日：2000-10-31

申请号：US294442

申请日：1998-08-13

申请人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

发明人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

IPC分类号： A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/566 ,  G01N33/569 ,  G01N33/53

CPC分类号： G01N33/566 ,  A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/56988 ,  G01N2500/04 ,  Y10S435/975

摘要： The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur. The use of secondary compounds for use in combinational, synergistic, therapy is also enclosed. These second compounds are also known to have some effect on the treatment of cellular pathologic changes, together with those compounds found to be effective upon the regulation of the Ah receptor the compounds can more beneficially control virally induced cellular cytopathic changes.

摘要翻译： 本发明包括治疗病毒感染的方法，特别是由人免疫缺陷病毒（HIV-1）感染的结果。 治疗方法取决于Ah受体的配体结合。 受体的转化和易位和DNA结合是不必要的。 与Ah受体（作为激动剂或拮抗剂）相互作用的化合物的研究已经导致通过扰动病毒致病信号转导途径鉴定具有有用治疗性质的化合物。 Ah受体的拮抗剂更可能是治疗的候选者，因为这些化合物的毒性低。 影响细胞靶标的分子的鉴定，如Ah受体，其抑制病毒病理信号传导将具有很大的治疗潜力，因为这些分子的活性不针对病毒本身，因此逃避这种治疗的遗传病毒突变将远远少于 可能发生 也包括使用二次化合物用于组合，协同治疗。 还已知这些第二化合物对细胞病理学变化的治疗具有一些作用，以及发现在调节Ah受体时有效的化合物可以更有利地控制病毒诱导的细胞病变变化。

公开(公告)号：US5833994A

公开(公告)日：1998-11-10

申请号：US780742

申请日：1997-01-08

申请人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

发明人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

IPC分类号： A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/566 ,  G01N33/569 ,  A01N65/00

CPC分类号： G01N33/566 ,  A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/56988 ,  G01N2500/04 ,  Y10S435/975

摘要： The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur. The use of secondary compounds for use in combinational, synergistic, therapy is also enclosed. These second compounds are also known to have some effect on the treatment of cellular pathologic changes, together with those compounds found to be effective upon the regulation of the Ah receptor the compounds can more beneficially control virally induced cellular cytopathic changes.

摘要翻译： 本发明包括治疗病毒感染的方法，特别是由人免疫缺陷病毒（HIV-1）感染的结果。 治疗方法取决于Ah受体的配体结合。 受体的转化和易位和DNA结合是不必要的。 与Ah受体（作为激动剂或拮抗剂）相互作用的化合物的研究已经导致通过扰动病毒致病信号转导途径鉴定具有有用治疗性质的化合物。 Ah受体的拮抗剂更可能是治疗的候选者，因为这些化合物的毒性低。 影响细胞靶标的分子的鉴定，如Ah受体，其抑制病毒病理信号传导将具有很大的治疗潜力，因为这些分子的活性不针对病毒本身，因此逃避这种治疗的遗传病毒突变将远远少于 可能发生 也包括使用二次化合物用于组合，协同治疗。 还已知这些第二化合物对细胞病理学变化的治疗具有一些作用，以及发现在调节Ah受体时有效的化合物可以更有利地控制病毒诱导的细胞病变变化。

公开(公告)号：US5529899A

公开(公告)日：1996-06-25

申请号：US98142

申请日：1993-07-27

申请人： Geoffrey D. Wheelock ,  John G. Babish

发明人： Geoffrey D. Wheelock ,  John G. Babish

IPC分类号： G01N33/15 ,  G01N33/53 ,  G01N33/566 ,  G01N33/567

CPC分类号： G01N33/5308 ,  G01N33/566 ,  G01N33/567 ,  G01N2430/40 ,  Y10S435/97 ,  Y10S435/975 ,  Y10S436/807 ,  Y10S436/809

摘要： The present invention is directed to a method of detecting dioxin-like compounds in a test sample. The test sample is contacted with a heteromer formed from a plurality of proteins, one of which is an inactive Ah receptor. If dioxin-like compounds are present in the test sample, they will bind to the Ah receptor causing it to dissociate from the heteromer as a complex containing active Ah receptor bound to a dioxin-like compound ligand. The presence of the complex is then detected. The process of the present invention can be practiced utilizing solid phase capture, competitive, and sandwich immunoassay test kit formats.

摘要翻译： 本发明涉及一种在测试样品中检测二恶英样化合物的方法。 将测试样品与由多种蛋白质形成的异源物接触，其中一种蛋白质是无活性的Ah受体。 如果二恶英样化合物存在于测试样品中，则它们将与Ah受体结合，导致其与作为与二恶英样化合物配体结合的活性Ah受体的复合物从异聚体解离。 然后检测复合物的存在。 本发明的方法可以利用固相捕获，竞争性和夹心免疫测定试剂盒形式来实施。